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Abstract
Nuclear all-trans retinoic acid receptors (RARs) initiate early transcriptional events which engage pluripotent cells to
differentiate into specific lineages. RAR-controlled transactivation depends mostly on agonist-induced structural transitions
in RAR C-terminus (AF-2), thus bridging coactivators or corepressors to chromatin, hence controlling preinitiation complex
assembly. However, the contribution of other domains of RAR to its overall transcriptional activity remains poorly defined. A
proteomic characterization of nuclear proteins interacting with RAR regions distinct from the AF-2 revealed unsuspected
functional properties of the RAR N-terminus. Indeed, mass spectrometry fingerprinting identified the Bromodomain-
containing protein 4 (BRD4) and ALL1-fused gene from chromosome 9 (AF9/MLLT3), known to associate with and regulates
the activity of Positive Transcription Elongation Factor b (P-TEFb), as novel RAR coactivators. In addition to promoter
sequences, RAR binds to genomic, transcribed regions of retinoid-regulated genes, in association with RNA polymerase II
and as a function of P-TEFb activity. Knockdown of either AF9 or BRD4 expression affected differentially the neural
differentiation of stem cell-like P19 cells. Clusters of retinoid-regulated genes were selectively dependent on BRD4 and/or
AF9 expression, which correlated with RAR association to transcribed regions. Thus RAR establishes physical and functional
links with components of the elongation complex, enabling the rapid retinoid-induced induction of genes required for
neuronal differentiation. Our data thereby extends the previously known RAR interactome from classical transcriptional
modulators to components of the elongation machinery, and unravel a functional role of RAR in transcriptional elongation.
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Introduction
Transcriptional activation by nuclear all-trans retinoic acid
(atRA) receptors (RARs) stems from the concerted action of
transcriptional coregulators whose role is to convert a repressive
chromatin environment into an opened state, allowing the
assembly of the transcription preinitiation complex (PIC).
Chromatin opening and PIC assembly are the end result of
ligand-induced conformational changes in the highly structured
C-terminal activating function (AF)-2 domain of DNA-bound
RARs, creating a protein-protein interaction interface that
recognizes LXXLL-containing transcriptional coregulators. Dis-
tinct families of transcriptional coregulators are recruited to the
RAR AF-2 in response to agonists, including the p160 family
(SRC1, TIF2/GRIP1, AIB1/ACTR/pCIP), CBP/p300, which
recruit or carry histone acetyltransferase activity, and the DRIP/
TRAP/Mediator complex which controls the basal transcription
initiation machinery [1].
The Rarb2 promoter is a paradigm for NR-mediated transacti-
vation, and has provided considerable insights into RAR-
controlled transcription. Detailed mechanistic studies using this
promoter showed that RARa-driven transcription requires, in
addition to the above mentioned transcriptional coregulators,
protein complexes involved in DNA breakage and repair such as
topoisomerase II, PARP-1 and PCNA [2–4] and appropriate post-
translational modifications of corepressors [5]. Furthermore,
histone H3 Serine10 (S10 H3) phosphorylation is concomitant to
retinoid-induced Rarb2 activation [6]. This histone mark is known
to favor the loading of the positive transcription elongation factor
b (P-TEFb) on regulated promoters, which is further facilitated by
BRD4/HUNK1, a bromodomain-containing transcription factor
with high affinity for acetylated histones H3 and H4 and Mediator
subunits [7–9]. Intriguingly, constitutively acetylated histones H3
and H4 reside at the Rarb2 promoter, favoring the permanent
loading of RXR-RARa heterodimers onto the retinoic acid
response element (RARE) located in this promoter [10]. In line
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with the possible involvement of P-TEFb in Rarb2 promoter
activation process, the kinase subunit of P-TEFb CDK9 associates
to this promoter in a ligand-controlled manner [11]. Thus a
functional role of P-TEFb in retinoid-induced activation of the
Rarb2 promoter can be hypothesized on the basis of this physical
colocalization.
Beside the ligand-regulated AF-2 region that encompasses the
ligand binding domain (LBD), RARs harbor other functional
domains such as the DNA binding domain (DBD) and the poorly
characterized, unstructured, ligand-independent N-terminal AF-1
domain. Little is known about the exact roles of RARa domains
outside of the LBD in transcriptional regulatory processes. In
addition to its recognized role in direct protein-DNA interaction,
the DBD interacts with transcription factors such as RXRs, c-jun,
BLZF1, NF-IL6, myb and TEL [12]. Similarly, RARa AF-1
engages into intra-molecular interactions with RARa AF-2 to
activate transcription, according to a mechanism involving the
recruitment of TFIIH subunits cyclin H to AF-2, and of the kinase
cdk7 to AF-1 [1]. We have therefore further investigated this
question by purifying putative RARa coregulators able to interact
with RARa domains distinct from the AF-2 domain. Mass
spectrometry fingerprinting confirmed that RARa AF-1 interacts
with the p62 subunit of TFIIH. More strikingly, this approach
revealed that the two mutually exclusive P-TEFb interactants
AF9/MLLT3 and BRD4/HUNK1 [13,14] bind to RARa in a
ligand-independent manner, evidencing a physical connection
between RAR and transcription elongation factors. AF9 and
BRD4 played distinct roles in retinoid-induced transcription and
neuronal differentiation as shown by microarray analysis of
mRNAs from the mouse pluripotent cell line P19. We further
show that RAR associates to transcribed regions of retinoid-
regulated genes in an AF9 and BRD4-dependent manner, and as a
function of P-TEFb activity.
Materials and Methods
Plasmids
Expression vectors for RAR and RXR, and reporter constructs
have been described [15]. pSG5-RARa-DAF-1, and pcDNA3-AF-
1 and pGFP-NLS-AF-1 were constructed by PCR amplification of
the Rara cDNA, followed by cloning in pSG5 (Stratagene, Santa
Clara, CA), in pcDNA3 (Invitrogen, Carlsbad, CA) and in
pEGFP-C1 (Clontech, Mountain View, CA) containing a nuclear
translocation signal (NLS), respectively. cDNAs corresponding to
the proteins identified by mass spectrometry were obtained as full
length open reading frame clones from the Mammalian Gene
Collection (N.I.H., Bethesda, MD) or from Origene (Rockville,
MD). They were amplified by PCR and inserted in the pCRII
vector by T/A cloning (Invitrogen). Cloned cDNAs were then
inserted as EcoRI/XbaI or XhoI/XbaI fragments in pCMV-
36FLAG (Sigma, St Louis, MN) for expression in mammalian
cells as a fusion with three FLAG epitope tags. The dominant-
negative mutant of CDK9 (cdk9 D167N, pCMV cdk9-HA dn,
[16] was a kind gift from A. Giordano (U.Penn., Philadelphia,
USA). The BRD4 cDNA fragment coding from residue 1 to 722
was cloned into pCMV-3xFLAG (Sigma). shRNA targeting Af9 or
Brd4 mRNAs were cloned in pSIREN (Clontech) using the
following oligonucleotides: Brd4: gatccgcctggagatgacatcgtcttattcaa-
gagataagacgatgtcatctccaggttttttctcgagg, Af9: gatccgtgagtgtgcaaa-
gacccaccttttcaagagaaaggtgggtctttgcacactcttttttttagatctg and their
complementary counterparts to generate ecotrophic retroviruses
according to the manufacturer instructions. Complete sequences
are available on request. All constructs were verified by automatic
sequencing (MWG Gmbh, Ebersberg, Germany). Other expres-
sion vectors were purchased from GeneCopoeia (Rockville, Md,
USA).
P19 Stable Clones Generation
Subconfluent P19 cells were transduced at MOI= 5 with
lentiviral particles and further selected with puromycin. Individual
clones were selected by the limited dilution method and
characterized for the expression of either Af9 or Brd4. Cell lines
displaying a mRNA decreased expression above 80% were further
characterized by western blotting. Initial experiments were carried
out on two individual, independent subclones.
Transient Transfections
HeLa or P19 cells were cultured as monolayers in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum
(Sigma). Transfections were carried out by the polyethyleneimine
coprecipitation method with Exgen500 (Euromedex, Souffel-
weyersheim, FR) as described [11]. Twenty four hours after
transfection, cells were treated overnight with 1 mM atRA and
luciferase activity was quantified. Basal expression levels were
arbitrarily set to 1 and data are expressed as the mean6SEM
(n= 3–6). Luciferase assays were performed with the BrightGlo
system (Promega, Madison, WI) and luciferase activity (as relative
luciferase units, RLU) was measured with a Victor Light 1420
Luminescence counter (Perkin-Elmer, Waltham, MA).
GST Pulldown Assays
The following GST-RARa fusion proteins were used in these
assays (Fig. 1E and Fig. S1A), with the numbers indicating the first
and last amino acid of the RARa sequence: GST-hRARa (1–462);
GST-AF-1 (1–92), GST-AF-1-DBD (1–158), GST-DBD (92–173);
GST-DBD-LBD (92–462), GST-LBD (186–462). Glutathione S-
transferase (GST) fusion protein expression and purification, and
GST pulldown assays were performed according to Rachez et al.
[17] with the following modifications. Immobilized GST fusion
proteins were incubated in GST-binding buffer consisting of
20 mM Tris-HCl, pH 7.9, 0.2 mM EDTA, 0.1% Nonidet P (NP)-
40, 0.5 mM PMSF, 1 mM DTT, protease inhibitors (Sigma),
containing 1 mg/mL BSA and 100 mM KCl. Immobilized
proteins on beads (20 mg) were incubated at 4uC for 6–10 hours
with 2–6 mg of HeLa nuclear extract; or 2 mg proteins on beads
were incubated at 4uC for 4 hours in the presence or absence of
atRA (Sigma) with proteins synthesized by in vitro translation
(TNT-coupled reticulocyte lysate, Promega) with 35S-methionine
(GE-Healthcare, Waukesha, WI). After three washes in GST-
binding buffer supplemented with 150 mM KCl and 0.3% NP-40,
samples were resolved by SDS-PAGE, and detected either by
silver nitrate staining or autoradiography followed by quantifica-
tion with a Storm 860 phosphorimager (GE-Molecular Dynamics).
Immunoprecipitation and Immunoblotting
Whole cell extracts from 105 transfected HeLa cells were
prepared in 0.25 mL lysis buffer [10 mM Tris?HCl, pH 7.5,
150 mM NaCl, 3 mM MgCl2, 0.5% NP-40, protease inhibitors
(Sigma) and 0.1 U DNaseI (Sigma)]. After centrifugation, cleared
extracts were diluted 5 times in lysis buffer without NP-40 and
incubated at 4uC for 3 hours with 80 mL anti-FLAG M2 affinity
resin (Sigma), or with the anti-RARa monoclonal antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) immobilized onto
protein A sepharose (GE-Amersham) pre-equilibrated in lysis
buffer. After four washes with lysis buffer adjusted to 0.15% NP-
40, samples were resolved by SDS-PAGE and detected by western
blot with appropriate primary antibodies, followed by incubation
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with HRP-coupled secondary antibodies and detection with ECL+
(GE-Amersham).
Mass Spectrometric Analyses
Protein samples resolved by SDS-PAGE were detected by
colloidal blue staining [17]. Bands were digested with trypsin and
analyzed by Matrix-assisted laser desorption/ionization time-of-
flight (Maldi-TOF) mass spectrometry. The SwissProt database
was interrogated through the MS-Digest Search program [18].
Spot excision and in gel digestion. Protein spots were
excised semi-automatically from 1D gels using the ‘‘Click and
pick’’ mode of the Ettan Spot Picker (GE-Amersham Biosciences).
Approximately ten plugs were excised from each band and put in
the same well. In-gel digestion was performed using an automated
protein digestion system (Ettan Digester; GE-Amersham Biosci-
ences). Briefly, plugs were washed three times with 50 mM
ammonium bicarbonate containing 50% methanol, then 50%
acetonitrile containing 0.1% TFA. After two washing steps in 70%
acetonitrile, plugs were dried and rehydrated with 10 mL of
20 mM ammonium bicarbonate containing 4 mg/mL trypsin
(Promega) for 4 hours. Finally, a 20 mM ammonium bicarbonate
solution was added overnight. The peptide mixture were then
dried, and resuspended in 10 mL 0.1% TFA before MALDI-MS
analysis.
Acquisition of mass spectrometric peptide maps, MALDI-
TOF MS and database search and analysis. 1 mL of peptide
mixture was mixed with 1 mL of DHB matrix solution (10 mg
dihydrobenzoic acid in 50% methanol) on the MALDI target.
MALDI-TOF MS was performed using a Voyager DE STR mass
spectrometer (PerSeptive Biosystems) equipped with a 337.1 nm
nitrogen laser and the delayed extraction facility. All spectra were
acquired in a positive ion reflector mode. Typically, 200 laser shots
were recorded per sample, and spectra were internally calibrated
(using the DataExplorerTM software, PerSeptive Biosystems)
using three peptides arising from trypsin autoproteolysis
([M+H]+842,5100; [M+H]+1045.5642; [M+H]+2211.1046).
Tryptic monoisotopic peptide masses were searched for in the
NCBI, using Protein Prospector (http://prospector.ucsf.edu/) with
a mass tolerance setting of 50 ppm, with three missed cleavage
sites as fixed parameters, and with carbamidomethylation and
methionine oxidation as variable modifications. The database
search identified multiple proteins in each band. However,
proteins to be further tested were chosen among the possible
candidates by comparing the relative abundance of the different
peptides, the percentage of recovery of each protein and taking
into account the full size of the proteins. MS analysis was carried
out 4 times on independent samples and selected peptides were
detected at least twice out of 4 analysis, but in most cases they were
detected 3 or 4 times out of 4 analysis. Proteins of interest were
selected from this type of analysis if peptide coverage was above
20%. Specific samples were re-analyzed and provided enhanced
spectra of protein digests which resulted in significantly increased
sequence coverage (above 35%) and confidence in protein
identification.
RT-QPCR
RNAs were extracted as described in [11]. RT-QPCR analysis
was carried out as described in [19]. When indicated, Taqman
assayson demand (Life Technologies, Foster City, CA) where used:
RARb2 Mm01319674_m1 and Mm01319678_m159; cdx1,
Mm00438172_m1*and m00438173_gH; Hoxa1
Mm04208064_g1* and Mm00439359_m1; Stra8
Mm01165138_m1 and Mm00486473_m1*; HoxB4
Mm00657964_m1 and Mm01307004_mH.
Microarray Analysis of mRNAs
Microrray hybridization and scanning were carried out
following the manufacturer instruction (Agilent, One-color Micro-
rray Gene Expression Analysis) using mouse SurePrint 8*60K
arrays. Data processing and analysis were performed as described
in [20] using the Genespring 12.0 software (Agilent). Briefly, array
integrity was visually inspected, and quality controls were
performed based on PCA analysis. Data were filtered to exclude
signals in the low 20% and averaged. A gene-level analysis was
performed and data filtered and graphed as detailed in the legend
to figures. Data were deposited on the ArrayExpress web site with
the accession number E-MEXP-3669.
Chromatin Immunoprecipitation Assays
ChIP assays were carried out in duplicate as described in [11]
using antibodies from Abcam (Cambridge, UK; AFF4, ab57077),
Santa Cruz [TFIIH, sc293; cdk9, sc8339; cdk8, sc1521; RARa,
sc551; RXRs, sc774; RNApol II, sc899; AF9(D17), sc32369;
AF9(L15); sc32371; Brd4(H250), sc48772], Bethyl Laboratories
(Montgomery, TX; AF9, A300-595A, A300-596A, A300-597A),
Active Motif (Carlsbad, CA; Brd4, #39909). Bethyl antibodies
were used as a 1:1:1 (vol:vol) mix in ChIP reactions; Brd4 was
immunoprecipitated with a v:v mix of Santa Cruz and Active
Motif antibodies. Results were acquired and quantified as
described in [21] and [22].
FRET Assays
Human RARa was cloned into pEGFP-C1 (Clontech, Palo
Alto, CA, USA) to be expressed as a C-terminal EGFP-fusion
protein. hRXRa, AF9 and Brd4 were cloned into the pReceiver-
M55 backbone (Genecopoeia, Rockville, Md, USA) to generate
mCherry-fusion proteins. Initial experiments showed that N-
terminally fused mCherry proteins, but not C-terminally fused
proteins, were suitable for FRET experiments together with the
EGFP-RAR. HeLa cells were plated on 32 mm diameter glass
Figure 1. The N-terminus of RARa interacts with nuclear proteins. (A) A nucleus-targeted RARa AF-1 domain acts as a dominant negative
receptor. HeLa cells were cotransfected with expression vectors coding for wild type (wt) RXRa, wtRARa, GFP-NLS and GFP-NLS-AF-1 at the indicated
ratio together with a mRarb2 promoter-driven reporter gene (mRARb2-Luc). Cells were treated overnight with 1 mM atRA and luciferase activity was
quantified. Basal expression levels were arbitrarily set to 1 and data are expressed as the mean6SEM (n= 3). *, p,0.05; **, p,0.01; ***, p,0.005.
(Right panel) Confocal laser microscopy of transfected HeLa cells. (B) The RARa AF-1 domain is transcriptionally active. HeLa cells were transfected
with mRARb2-Luc and expression vectors coding for wtRXRa, wtRARa, N–terminally DAF-1-RARa) or C-terminally truncated DAF-2-RARa) RARa. Cell
treatment, luciferase assays and calculations are as in (A). (C, D) Isolation and identification of proteins interacting with the AF-1 transactivation motif
of RARa. AF-1 fused to GST (GST-AF-1) or GST alone (GST) were immobilized on a matrix and incubated with HeLa nuclear extracts (+HeLa) or buffer
alone (Mock). Numbers indicate bands that were subjected to mass spectrometry analysis. (D) The table indicates the name, protein abbreviation, the
UniProtKB/TrEMBL entry, percentage of peptide coverage in two representative purifications, and the predicted molecular mass. (E) Target validation
by GST pulldown assays. Various domains of RARa were expressed as fusion proteins to GST (left panel) and used as baits for 35S-labeled shortBRD4
(sBRD4), AF9, PAK6 and NAP1L2. CB: Coomassie Blue staining of RAR derivatives adsorbed on glutathione-Sepharose. (F) Interaction of RARa with
BRD4 or AF9. FLIM-based FRET fluorescence assays were performed to determine the lifetime of the donor (GFP) in the indicated conditions.
doi:10.1371/journal.pone.0064880.g001
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coverslips 12 h before transfection with the FuGENE HD reagent
(Roche Diagnostics, Rotkreuz, SW) according to the manufactur-
er’s recommendations. For FLIM-FRET imaging, the glass
coverslips were deposited into a POC (Perfusion, Open and
Close) chamber and the culture medium was replaced by
Leibovitz’s 15 medium (L-15, Invitrogen). The frequency-domain
FLIM measurements have been previously described in Leray et al
[23]. The FLIM microscope is composed of a LIFA system
(Lambert Instruments, Roden, The Netherlands) implemented on
a spinning-disk confocal system (Yokogawa CSU-X1, Tokyo,
Japan) adapted on a Leica (Lognes, FR) DMI6000B inverted
microscope and equipped with a diode laser source emitting at a
wavelength of 488 nm and whose intensity is modulated at
40 Mhz. Cells were imaged using a 636 oil-immersion objective
(Leica HCX Plan Apo NA 1.4). Fluorescence emitted was then
successively routed by a dichroic mirror (Semrock Di01-T405/
488/568/647), spectrally filtered (Chroma, HQ545/306) and
detected with an intensified CCD camera (Li2CAM, Lambert
Instruments) modulated at the same frequency (40 MHz) and
coupled to an optical zoom (62). The phase fluorescence lifetime
for each sample was calculated from the acquisition of 36 phase-
shift images using the LI-FLIM software (Lambert Instruments),
after calibrating the system with a reference fluorescein solution at
1 mM of known lifetime (4 ns). For each set of acquisition, means
and standard error of the means (S.E.M.) were determined from at
least 8 samples per condition using the GraphPad Prism v5.0
software (San Diego, CA).
Statistical Analysis
Values are reported as the mean6SEM, with 3–6 biological
replicates (gene expression data). The statistical significance of
differences amongst groups were determined using either a
Student t-test (2 group) or ANOVA followed by a post-hoc test
(Tukey) using GraphPad Prism v5.0. *, p,0.05; **, p,0.01;
***, p,0.005.
Results
RARa Interacts with Components of the SEC Complex
The AF-1 domain of RARa functions as an autonomous
transactivation domain, as shown by squelching experiments in
Hela cells using overexpressed, nuclear-targeted GFP fused to
RARa AF-1 (Fig. 1A) and the defective transcriptional activity of
RARa deleted from its N-terminal AF-1 domain (DAF-1-RARa,
Fig. 1B), as previously reported in COS cells [24]. We thus
identified novel RARa transcriptional coregulators using mass
(MALDI-TOF) fingerprinting of HeLa nuclear proteins binding to
the isolated RARa AF-1 domain (Fig. 1C and 1D). The p62
subunit of TFIIH (BTF2), known to interact physically and
functionally with RAR AF-1 [25,26] was isolated, thus validating
our experimental strategy. Isolated proteins interacted with RARa
in a ligand-independent manner, and included the novel potential
coregulators PAK6 (p21-activated kinase-6), AF9/MLLT3 (ALL1
fused gene from chromosome 9), NAP1L2 (nucleosome associated
protein 1-like 2) and the short isoform of BRD4 (70–80 kDa,
sBRD4). Although full-length Brd4 has been described in HeLa
cells as occurring as a 180–200 kDa polypeptide [27], all of the
identified peptide sequences mapped within the sequence of
sBRD4, in agreement with a number of reports describing BRD4
as a lower molecular mass polypeptide of ca. 70–80 kDa [28,29].
Unexpectedly, we also identified RARc as an AF-1 interactant.
This suggested that RAR can homodimerize through this region
and the LBD, a hypothesis which was confirmed by GST
pulldown assays using labeled RARa deletion mutants and
GST-hRARa AF-1. This assay indeed revealed that the RAR
AF-1 interacts mostly with the LBD, hinting at inter-domain
interactions (Fig. S1A). Therefore, our GST affinity matrix was
constituted not only of the isolated AF-1, but also included full-
length RARc, and thus might have adsorbed proteins interacting,
in a ligand-independent manner, not only with the isolated AF-1,
but also with full length RARc. Detected interactions were
therefore validated using either the full length RARa or various
RARa deletion mutants fused to GST as baits (Fig. 1E). All
proteins interacted with full length RARa and showed a strong
propensity to associate to the isolated RAR DBD. Preliminary
experiments ruled out a possible contribution of the hinge region
to the observed interactions (CR and PL, unpublished observa-
tions). PAK6, already described as an androgen and estrogen
receptor corepressor [30,31], and TFIIH were not considered
further. Thus only AF9 interacted detectably with the isolated AF-
1 domain, as shown by GST pulldowns and coimmunoprecipita-
tion assays (Fig. 1E and Fig. S1B). AF9 and BRD4 were thus
chosen for further study, as both potentiated RARa transcriptional
activity without interacting with the RARa LBD (Fig. 1E), in
contrast to NAP1L2, which, in addition, was inactive in the
transcription assay (Fig. S1C). Molecular interactions were further
assessed by fluorescence resonance energy transfer (FRET) in
living Hela cells. The use of N-terminally tagged proteins (eGFP
for RARa, mCherry for RXRa, AF9 and Brd4) showed a
significant decrease of the donor lifetime (eGFP) coupled to RARa
in the presence of the known RAR dimerization partner acceptor
RXRa. Similarly, both AF9 and Brd4 induced a decrease of the
donor lifetime, showing clearly that these proteins interact closely
with RARa. Interactions were not modified upon treatment with a
synthetic pan-RAR agonist (TTNPB), confirming that these
interactions are ligand-independent (Fig. 1F).
RARa-mediated Transcription is P-TEFB-dependent
P19 EC cells (noted P19wt thereafter) are stem cell-like,
pluripotent cells differentiating into neurons and glial cells upon
atRA treatment [32]. In this cell line, as well as in other mouse EC
cell lines, the Rarb2 promoter is the archetypical atRA-regulated
promoter, harboring a consensus DR5 retinoic acid response
element (RARE) and potential cis-acting motifs for COUP-TFI/
NR2F1 and CREB (Fig. 2A). atRA, but not overexpressed COUP-
TFI or cAMP, induced Rarb2 expression in P19 cells (Fig. 2B),
showing that the DR5 RARE is a major functional cis-acting
element. As expected, the mRNA expression of the pluripotency
marker Pou5f1/Oct4 was downregulated in response to atRA,
whereas that of control genes Top2b, Tcf19 and Rplp0 was
unaffected (Fig. 2B). In these conditions, a ligand-dependent
binding of RARa to the negative RARE from the Pou5f1 promoter
[33] was detected by chromatin immunoprecipitation (ChIP)
assays, performed with a specific anti-RARa antibody [11,34]
(Fig. 2C). RARa binding was concomitant to decreased RNA
polymerase II (RNApol II) C-terminal domain (CTD) phosphor-
ylation (S5P-RNApol II), a post-translational modification associ-
ated with promoter clearance and increased transcription. In
similar conditions, S5P-RNApol II, but not RARa, associated to
the retinoid-insensitive Rplp0 ribosomal gene promoter (Fig. 2C).
Thus the atRA-induced activity of the Rarb2 promoter depends
mostly, if not exclusively, on RAR-driven events.
ChIP assays showed that RARa was constantly bound to the
Rarb2 promoter, which harbored high levels of acetylated H3
histone irrespective of the presence of ligand (Fig. 2D and [6]), in
agreement with the facilitating effect of histone acetylation on the
binding of RAR-RXR heterodimers to nucleosomal DNA [10]. In
contrast, a decreased density in the P-TEFb kinase subunit CDK9
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and AF9 (Fig. 2D), known to associate to P-TEFb [35], was
observed. Increased densities of phosphorylated histone H3
serine10 (P-S10 H3), of total (RNApol II) and of S5P-RNApol II
were concomitant to Rarb2 activation, in agreement with the
increased loading of the RNApol II kinase TFIIH (Fig. 2D and
[11]).
P-TEFb catalyzes the phosphorylation of RNApol II on Ser2
and of the negative elongation factors NELF and DSIF [DRB (5,6-
dichloro-1-b-D-ribofuranosylbenzimidazole) sensitivity-inducing
factor] to promote the release of paused RNApol II [36]. DRB
inhibited atRA-induced accumulation of Rarb2 mRNA in P19wt
with an EC50<5 mM, suggesting that CDK9 activity is necessary
for Rarb2 promoter activation (Fig. 2E). Similarly, increasing
amount of a dominant-negative (dn) mutant of CDK9 (CDK9
D167N) blunted Rarb2 promoter activation (Fig. 2F). Thus the
sensitivity of the Rarb2 promoter to CDK9 inhibition reflects the
association of this chromatinized cis-acting sequence to the P-
TEFb kinase CDK9 (Fig. 2D).
Involvement of P-TEFB in Retinoid-mediated
Transcription
The interaction of RARa with P-TEFb interactants raised the
possibility that it could associate with elongating complexes.
RARa association with various intronic or exonic regions of the
Rarb2 locus was monitored by ChIP assays in P19 cells (Fig. 2G
and 2H). RARa association with an intronic region occurred
only after atRA treatment, and could also be observed, albeit to
a much lower extent, downstream of the transcription termina-
tion site which mapped to the retinoid-insensitive 59-flanking
Top2b gene (Fig. 2G). ChIP-ReChIP assays demonstrated a
colocalized, ligand-dependent accumulation of RAR and S5P-
RNApol II on these transcribed regions (Fig. 2G). Thus RAR
colocalizes with elongating RNApol II. To evaluate whether P-
TEFb activity affects RAR association to transcribed regions of
the Rarb2 gene, P19wt were treated with TTNPB with or
without the CDK9 inhibitor flavopiridol (Fig. 2H). While
flavopiridol did not perturb RAR recruitment to the Rarb2
promoter and tended to decrease RNApol II density at this
location, it clearly decreased the atRA-induced accumulation of
RNApol II and of RAR at several exonic regions. Thus P-TEFb
activity is required for RAR association to Rarb2 transcribed
regions. This observation was unexpected in the light of a
previous report showing that RAR is absent from exon 6 of the
Rarb2 gene in atRA-treated HeLa cells [37]. Although BRD4 or
AF9 are readily expressed in these fibroblastic cells, the high
level of sequestration of P-TEFb in an inactive from in this
rapidly proliferative cell line may explain this discrepancy [38].
Moreover, RAR displays a distinct binding kinetics with the
RARb2 RARE, which, in non-differentiating HeLa cells, cycles
over time with a period of 4 hours [37] but decreases over time
in EC F9 cells [39], thus pointing to distinct cell-specific
transcriptional activation mechanisms.
Functional Relevance of AF9 and BRD4/RARa Interaction
in Retinoid-regulated Transcription
AF9 overexpression strongly potentiated the basal expression
level of the Rarb2 gene without affecting its ligand responsive-
ness in P19wt (Fig. 3A), in agreement with its ligand-
independent interaction with RARa (Fig. 1). The short isoform
of BRD4 (sBrd4) exerted a significant effect on retinoid-induced
RAR activity, whereas the full length BRD4 (lBrd4) was mostly
active on the basal expression of the Rarb2 gene (Fig. 3B).
Conversely, shRNA-mediated knockdown of Af9 or of Brd4
expression strongly blunted Rarb2 expression in P19 subclones
[noted P19Af9(2) and P19Brd4(2), (Fig. 3C)]. To assess whether
BRD4 and/or AF9 could play a role in transcription elongation,
we assayed the abundance of Rarb2 mRNA using exon-specific
PCR primer sets (Fig. 3D). After a 4 hour-induction, P19wt
accumulated about half the amount of full length transcript
when compared to 59 transcripts, suggesting a fast initiation
process but a poor processivity. Amplification of exon sequences
showed that the loss of processivity occurred between exon 6
and exon 7 of the Rarb gene, which may relate to yet undefined
particular chromatin structures. We noted that the loss of
processivity was not significant in Brd4-depleted cells. In
contrast, P19Af9(2) and P19Brd4(2) accumulated less 39-truncated
transcripts (or produced less abortive 59 transcripts), suggesting
that these AF9 and BRD4 act mainly on initiation or early
elongation events.
Transcription Elongation Factors and RAR Associate to
the Rarb2 Gene Body
P-TEFb has been shown to bind to SEC, which contains the
core component AFF4 and the coactivating AF9, or to BRD4
[38,40]. TFIIH also participates in transcriptional elongation
[41]. The recruitment of these factors to the Rarb2 locus, as
well as that of RAR and RXR, was thus monitored after
retinoid treatment (Fig. 3E). In P19wt, RNApol II was found
within transcribed regions and at the promoter like the TFIIH
subunit cdk7, whereas AFF4 density increased within the gene
body. AF9 associated preferentially to the promoter region but
was detected at significant levels at exonic regions, and BRD4
accumulated at the 39 end of the gene. RAR was detected both
at the promoter and exonic regions, whereas its heterodimeric
partner RXR was surprisingly detected only at the promoter.
P19Brd4(2)displayed a decreased RNApol II density throughout
Figure 2. RAR localizes to transcribed regions of the Rarb2 gene in a P-TEFB-dependent manner. (A) Structure of the mouse Rarb2
promoter. pRARE: proximal RARE; dRARE: distal RARE. (B) Gene expression in P19 cells. P19 cells were treated for 48 hours with DMSO, 1 mM all trans
RA (atRA), 250 mM cAMP or transfected with a HA-tag COUP-TFI expression vector. Expression of Rarb2, Top2b, Creb, Coup-TFI, Tcf19 and Rplp0 were
quantified by RT-QPCR. Basal expression levels were arbitrarily set to 1 and data are expressed as the mean6SEM (n= 3). *, p,0.05; **, p,0.01; ***,
p,0.005. (C) RARa and phosphorylated RNApol II loading at the Rplp0 and Pou5f1/Oct4 promoters. P19 cells were treated as in (B) and ChIP assays
were performed with indicated antibodies. (D) AF9 colocalizes to the Rarb2 promoter. P19 cells were treated for 4 hours with 1 mM atRA, and ChIP
assays were carried out as described. The specific enrichment in Rarb2 promoter sequence is expressed after normalization to background values
(Myoglobin gene). Data are expressed as the mean6SEM (n= 2). *, p,0.05; **, p,0.01; ***, p,0.005. (E) DRB inhibition of the Rarb2 gene
transcription. P19 cells were treated with the indicated combination of atRA (1 mM) and varying doses of DRB (50 to 5000 nM) for 4 hours. Rarb2
mRNA was quantified by RT-QPCR. (F) A CDK9 dominant negative mutant inhibits Rarb2 gene expression. P19 were cotransfected with increasing
amount of pCMV-lacZ (control), pCMV-HA-wtCDK9, or pCMV-HA-dnCDK9 expression vectors at the indicated ratio, then treated 24 hours with 1 mM
atRA. Gene expression was quantified as above and data expressed as the mean6SEM (n= 4). *, p,0.05; **, p,0.01; ***, p,0.005. (G) RAR and
phosphorylated RNApol II are detected at transcribed regions of the Rarb2 gene. P19 cells were treated as in (D) and ChIP/reChIP assays were
performed. (H) P-TEFb inhibition prevents RAR association to Rarb2 elongated regions. P19 cells were treated for 4 hours with the indicated
combination of TTNPB (1 mM) or flavopiridol (250 nM). ChIP assays (n = 2) were performed as in (D).
doi:10.1371/journal.pone.0064880.g002
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the Rarb2 locus, in agreement with the observed diminished
Rarb2 mRNA synthesis. AFF4 and AF9 densities were barely
affected, however cdk7 association was decreased. Brd4 knock-
down also impacted negatively on RAR loading in elongated
regions. In contrast, Af9 silencing globally increased RNApol II,
BRD4, RAR and, to a lower extent, AFF4 loading. This
suggested that AF9 exerts a negative effect on BRD4
recruitment, and that the observed decreased transcriptional
activity of Rarb2 upon AF9 depletion may correlate with
decreased RNApol II processivity. Importantly, the cdk9
inhibitor DRB significantly blunted the transcriptional activity
of full length RARa in the presence of atRA, but was much less
efficient on the transcriptional activity of the N-terminally
truncated RARa (DAF-1-RARa, Fig. 3F), suggesting that AF-1
integrity is required to confer P-TEFb dependency to RAR-
mediated transcription.
AF9 and BRD4 Regulate Distinct Retinoid-regulated Gene
Clusters
Retinoids trigger neuronal differentiation of P19 cells by
regulating a network of RAR-driven genes. Indeed, 188 and 66
genes were up- or down-regulated respectively by more than 2-fold
after a 4 hour-treatment of P19 embryoid bodies with atRA (Fig.
S2A and Table S2). Functional annotation of these genes
identified clusters of genes involved in embryo development and
patterning (Fig. S2B), showing that P19 cells recapitulate initial
transcriptional events leading to neuronal differentiation. For
example, genes from the Hox cluster were significantly upregu-
lated, as well as Cyp26a1, involved in the catabolism of RA.
We first asked whether BRD4 or AF9 played a role in
controlling gene basal expression levels. While 31,948 genes were
significantly expressed in P19wt, only 397 or 459 genes were up- or
down-regulated by more than 5-fold in untreated P19Brd4(2) or
P19Af9(2), respectively (Fig. S3). Among these 2 sets of genes,
Hoxa4 was the only known retinoid-target gene to be down-
regulated in both cellular backgrounds (Table S2), showing that
these two elongation factors do not contribute to basal transcrip-
tion of retinoid-regulated genes.
Gene expression levels were determined after a 4-hour
treatment of P19wt with the RAR-specific agonist TTNPB.
The gene program induced by this synthetic ligand was very
similar to that induced by atRA (91% overlap, Fig. S4 and
Table S3). Gene expression levels in stimulated conditions
(TTNPB, 4 hours) were calculated for each cellular background
and expressed as fold-change over basal levels in P19wt set to 1
for each gene (Fig. 4A and 4B). While examination of the gene
expression pattern (Fig. S5A) showed a limited perturbation of
the P19wt transcriptome, a gene-by-gene analysis revealed that
genes involved in cellular differentiation displayed a differential
sensitivity to BRD4 or AF9 levels (Fig. 4A). Importantly, many
known atRA-target genes were selectively affected by AF9 or
BRD4 silencing (Fig. 4B), pointing at distinct functions of these
two elongation factors in atRA-induced transcription. This
conclusion was validated by the fact that AF9 depletion did not
affect P19 cell differentiation, as assayed by the increased
expression of the 160kDa neurofilament, while Brd4 knockdown
blocked this process (Fig. S5B).
BRD4 has been recently described as having a limited
contribution to the rapid induction of a subset of retinoid-
regulated genes, in contrast to SEC which had a broad impact on
this process in mouse ES cells [35]. We thus investigated whether
BRD4 or/and AF9 could contribute directly to the rapid
induction of RAR-controlled genes in P19 cells. Genes displaying
a maximal expression (FC.2) after a 60 min.(cluster I, Fig. 5),
120 min. (cluster II, Fig. 5) or 240 min. (cluster III, Fig. 5)
treatment with TTNPB were identified in P19wt cells. The
expression of these clusters was monitored in P19Brd4(2) or
P19Af9(2) to show that early-induced genes (clusters I and II) were
more sensitive to Brd4 or Af9 knockdown than genes from cluster
III. Thus both BRD4 and AF9 affect differentially atRA-regulated
gene expression in our system, and favor the rapid induction of a
limited set of genes.
AF9- and BRD4-independent Genes Do Not Recruit RAR
to Promoters and Transcribed Regions
A close examination of the gene expression pattern by fold
expression over time (Fig. 4D) also showed that some retinoid-
regulated genes were insensitive to BRD4 or AF9 depletion.
Gene expression data were therefore organized in 4 clusters of
genes maintaining, or not, a significant induction rate (more
than 50% of the gene activity in the wild type background)
upon TTNPB treatment (4 hours, Fig. 6, top panel) in
P19Brd4(2) or P19Af9(2) backgrounds. Four clusters were defined
on the basis of gene induction sensitivity to BRD4 or AF9
depletion (AF9 and BRD4-independent, cluster A; BRD4-
dependent and AF9-independent, cluster B; AF9-dependent
and BRD4-independent, cluster C; AF9- and BRD4-dependent,
cluster D). Three genes within each cluster harboring a RAR
binding site within 30 kb of the gene boundaries as documented
in mouse ES cells (Table S1, [42]) were selected for further
characterization. The recruitment of RAR and of RNApol II
was monitored by ChIP-PCR assays, due to the length of
selected sequences, in TTNPB-treated P19wt cells at either a
control upstream region devoid of potential RARE (UR), at the
identified RAR DNA binding site (RAR BS), at the transcrip-
tion start site (TSS) or within an exon without potential RARE
(Exon, Fig. 6). Control UR associated neither to RAR nor to
RNApol II in these conditions, while RAR was consistently
Figure 3. AF9 and BRD4 coactivate RARa in a ligand-independent manner. (A, B) P19 cells were transfected with the indicated amounts of
AF9, sBRD4 or lBRD4 expression vectors for 24 hours with or without 1 mM atRA and Rarb2 gene expression was assayed by RT-QPCR. The basal
expression level in non transfected, untreated cells was arbitrarily set to 1 and data were expressed as the mean6SEM (n= 5). *, p,0.05; **, p,0.01;
***, p,0.005. (C) Af9 or Brd4 knockdowns. (C, upper panel) AF9 or BRD4 expression was assayed by western blot analysis in P19wt, P19Af9(2) and
P19Brd4(2). (C, lower panel) Rarb2 gene expression in AF9- or BRD4-depleted P19 cells. The time-dependent expression of Rarb2 upon stimulation with
1 mM TTNPB was quantified by RT-QPCR. (D) Exon-specific RT-QPCR assay of the Rarb2 mRNA. Cloned mRarb2 cDNA was used as a standard in PCR
reaction, and used to select PCR primer sets displaying a similar efficiency (‘‘Cloned cDNA’’). Rarb2mRNA from either P19wt, P19Af9(2) or P19Brd4(2) was
then formally quantified by Q-PCR. **, p,0.01, intra-sample comparison; 11, p,0.01, inter-sample comparison. (E) RAR associates to Rarb2 transcribed
regions as a function of AF9 and BRD4 levels. P19wt, P19Af9(2) or P19Brd4(2) were treated with 1 mM TTNPB for 1 hour and ChIP assays were performed.
The specific enrichment in the different Rarb2 amplicons was assayed by Q-PCR and expressed normalized to background values (myoglobin gene).
Data are expressed as the mean6SEM (n= 2). *, p,0.05; **, p,0.01; ***, p,0.005. (F) The AF-1 region of RAR confers DRB sensitivity to RA-induced
transcription of the Rarb2 promoter. P19 cells were cotransfected as indicated with expression vectors coding for wtRXRa, wtRARa or DAF-1-RARa or
DAF-2-RARa together with the mRARb2-Luc reporter gene. Cells were treated 24 hours with 1 mM atRA and/or DRB and luciferase activity was
quantified. Basal expression levels were arbitrarily set to 1 and data are expressed as the mean6SEM (n= 6). *, p,0.05; **, p,0.01; ***, p,0.005.
doi:10.1371/journal.pone.0064880.g003
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Figure 4. Gene expression level in response to RARa activation in wild type, AF9- and BRD4-deficient backgrounds. (A) Genes
exhibiting a fold-change above 1.2 fold in TTNPB-treated P19wt cells were clusterized according to a functional gene ontology classification.
Representative functional clusters from the top 10 hits are shown. The basal level in non treated P19wt was arbitrarily set to 1 and is depicted by black
boxes. Numbers indicate the fold change ratio of individual genes relative to untreated wt P19 (red: upregulation; green: downregulation; black, no
change). (B) Gene expression levels of known atRA-target genes. RA-target genes were selected from the literature and their expression levels were
extracted from microarray data. Results are represented as in (A).
doi:10.1371/journal.pone.0064880.g004
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detected at RAR binding sites. RNApol II accumulated at TSS
and exonic regions, as expected from increased mRNA
transcripts synthesis (left inserts, Fig. 6). In contrast to AF9-
and/or BRD4-dependent genes (clusters C and B respectively),
RAR association to either TSS or exonic regions was not
detectable for AF9- and BRD4-independent genes (cluster A,
Ccdc88b, Cdh18, Csn3), suggesting that these factors are required
for RAR recruitment, or at least stable binding, to elongated
regions. It also suggested that the retinoid-mediated activation
of BRD4 and/or AF9-dependent genes differs significantly from
those exhibiting no such dependency, as emphasized by the
selective accumulation of RAR at the TSS from BRD4- and
AF9-dependent genes.
Figure 5. Time-dependent induction of gene expression upon RARa activation in P19wt, P19Af9(2) or P19Brd4(2). Cells were treated with
TTNPB for indicated times and gene expression patterns were monitored. Genes induced more than 2-fold and peaking at either 60 minutes, 120
minutes or 240 minutes in the P19wt background were clusterized to define cluster I (peaking at 60 minutes), cluster II (peaking at 120 minutes) and
cluster III (peaking at 240 minutes). Associated gene lists were used to generate entity lists in Genespring to follow the expression of these genes in
the P19Af9(2) or P19Brd4(2) background. Expression at different times in distinct cellular backgrounds is displayed as a heatmap.
doi:10.1371/journal.pone.0064880.g005
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AF9 or BRD4 Stabilize RAR Interaction with Transcribed
Regions
Given that RAR did not associate to exonic regions of genes
from cluster D (ie AF9- and BRD4-independent), we characterized
RAR occupancy in the P19Brd4(2) or P19Af9(2) background (Fig. 7).
In good agreement with gene expression data, ChIP-QPCR assays
revealed that TSS occupancy by either BRD4 or AF9 could be
detected at BRD4 and/or AF-dependent genes (clusters B, C and
D), but not at the TSS of BRD4- and AF9-independent genes
(cluster A). Silencing of Af9 or of Brd4 did not modify RAR loading
at any of the locations tested in genes from cluster A. RAR loading
in AF9-dependent genes (cluster B) was not affected by BRD4
Figure 6. RARa association to transcribed regions in AF9-or BRD4-independent genes. The response of TTNPB-inducible genes (FC.2
after 4 hours) in P19wt was compared to that in P19Af9(2) or P19Brd4(2) in similar conditions. Genes losing their responsiveness to TTNPB (FC,1.2) in
either the P19Brd4(2) background (cluster B), the P19Af9(2)background (cluster C) or both (cluster D) were identified by microarray data analysis. Genes
maintaining an inducibility similar to that observed in P19wt in either the P19Af9(2) or the P19Brd4(2) background were grouped in Cluster A. Genes in
each cluster were searched for the occurrence of RAR binding sites on the basis of RAR ChIP-Seq data carried out in mouse ES cells [42]. Three
representative genes were selected from each cluster and their inducibility was validated by RT-QPCR in each condition (n = 3, left inset). RARa and
RNApol II association to an upstream region (UR), RAR binding site (RAR BS), transcriptional start site region (TSS) and an exon (Exon) was assessed in
independent, duplicate ChIP-PCR assays after a 4-hour challenge of P19wt with TTNPB. Input lanes showed an equal loading but were omitted for
space purposes.
doi:10.1371/journal.pone.0064880.g006
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depletion. In contrast, Af9 knockdown impaired RAR association
to exonic regions, whereas binding to the ‘‘RAR BS’’ was not
significantly affected. BRD4-dependent genes (cluster C) mirrored
this response, since only Brd4 silencing affected RAR density at
exonic sequences. Furthermore, AF9- and BRD4-dependent genes
reflected the behavior of the Rarb2 gene, for which Brd4 silencing
reduced RAR association to transcribed regions and Af9
knockdown had an opposite effect. As BRD4 and AF9 were
shown to belong to distinct complexes and to interact with RAR
DBD, their partitioning was assessed by coimmunoprecipitation of
endogenous proteins from P19 cells. These assays showed that
while immunoprecipitation of RARa isolated a fraction of BRD4
or of AF9, immunoprecipitation of AF9 was exclusive of that of
BRD4, and vice-versa (Fig. S6). These experiments show that
either BRD4 or AF9 is sufficient for RAR association to
transcribed regions, and suggests that AF9 has an inhibitory role
on RAR-BRD4 association.
Discussion
In the current study, mass spectrometry-fingerprinting was used
to identify AF-2-independent RARa coactivators. The unexpected
interaction of RARa with RARc led to the identification of BRD4
and AF9 as interacting strongly with the DNA-binding domain of
RARa, and to a lesser extent with the N-terminal AF-1 domain in
the case of AF9. Using the Rarb2 promoter as a paradigm for
RAR-mediated transcription, we demonstrate that both proteins
displayed RARa coactivating properties, thus functionally and
physically connecting RAR to P-TEFb (cyclinT:CDK9), which
interacts in an exclusive manner with BRD4 or AF9 [38]. In
addition, we observed that RARa can associate to transcribed
regions together with RNApol II. CDK9 catalyzes RNApol II
CTD Ser2 phosphorylation, allowing the release of paused
RNApol II complex for productive RNA elongation by relieving
the inhibitory action of the DRB sensitivity-inducing factor DSIF
and of the negative elongation factor NELF [reviewed in [36]].
Both the pharmacological inhibition of the P-TEFb kinase CDK9
and AF9 depletion blunted Rarb2 gene transcription. RNApol II
processivity is controlled by AF9, which directly or indirectly
regulates positively CDK9 activity [43]. Thus a decreased
RNApol II processivity in Af9-depleted P19 cells (Fig. 3E) may
account for the increased RAR and RNApol II association to gene
body sequences and the observed decreased gene transcription.
BRD4 is known to bind to both components of P-TEFb, cyclinT
and cdk9 [27]. It preferentially associates to P-TEFb at the
promoter-proximal regions of Ca2+- or of HIV1-regulated genes
and is excluded from AFF4-containing complexes [43–47]. BRD4
is however required for the induction of the HIV-1 promoter [8],
and show a preferential activity on primary response genes [48].
The negative impact of Brd4 silencing on some rapidly induced
genes in our system (Fig. 5) is in agreement with this observation
and suggests that retinoid-controlled transcription may depend
Figure 7. AF9 or BRD4 are required for RAR interaction with exonic regions. Two representative genes from clusters defined in Figure 5
were selected. The loading of AF9 and BRD4 to the TSS was assayed by ChIP-QPCR (n = 2) and results normalized to background values (Myoglobin
gene) are represented in left insets (bar graphs). The association of RAR to an upstream region (UR), RAR binding site (RAR BS), transcriptional start
site region (TSS) and an exon (Exon) was assessed in independent, duplicate ChIP-PCR assays after a 4-hour challenge of P19wt, P19Brd4(2) or P19Af9(2)
cells with TTNPB. Data are expressed as the mean6SEM (n= 2). *, p,0.05; **, p,0.01.
doi:10.1371/journal.pone.0064880.g007
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either on the SEC or on the BRD4 version of P-TEFb.
Interestingly, BRD4 is required for the rapid induction of a subset
of retinoid-regulated genes (our study and [35]), and favors P-
TEFb loading due to its affinity for phosphorylated H3Ser10 and
acetylated histones H3 and H4 [7,27,49]. Importantly, all of these
epigenomic marks are present at the archetypical Rarb2 promoter,
whose expression is dependent on BRD4 levels (our study and
[11]). FRET studies showed convincingly that RARa interacted
directly not only with AF9 but also with BRD4 in living cells,
suggesting that RARa may constitute a landing pad for BRD4 on
retinoid-activated promoters.
An unexpected finding was that some retinoid-regulated genes,
including Rarb2, display a similar dependency on BRD4 and AF9
expression. The mutually exclusive binding of P-TEFb to BRD4
and AF9, as well as the similar binding interface on RARa, rules
out the co-occurrence of BRD4 and AF9 into the same complex.
The observation that AF9 depletion favors BRD4 and RAR
recruitment to transcribed regions, yet promotes a decreased
transcription efficacy, suggests that BRD4 plays, for this specific
cluster (Fig. 6, Cluster D), a moderate role in transcriptional
regulation. This is in line with the reported broad distribution, but
restricted regulatory role of BRD4 in ES retinoid-regulated genes
[35].
The selective recruitment of RAR, but not of RXR, to
transcribed regions depending on P-TEFb activity is an unprec-
edented observation. The functional role of this association is likely
to increase transcriptional efficiency, as shown by the loss of rapid
gene induction upon Brd4 or Af9 knockdown and RAR association
to gene bodies. Indeed, the Hoxb1 gene, which is poorly inducible
in our system, is weakly activated in mouse ES cells and does not
recruit the SEC complex upon retinoic acid challenge [35]. In
contrast, both Hoxa1 and Cyp26a1 are strongly induced in both
systems and recruit SEC in mouse ES cells. This correlates SEC
loading to rapid transcriptional induction, and both AF9 and
BRD4 depletion preferentially affected early-induced genes in our
model. Our present work, together with published data [50–52],
thus show that nuclear receptors can engage physical and
functional interaction with the transcriptional elongation machin-
ery, thus providing a mechanistic basis for SEC targeting to
conditionally-activated promoters.
In this study, we thus report the following original findings: (i)
the P-TEFb interactants BRD4 and AF9 bind directly to and
coactivate RAR in living cells; (ii) the activation of the archetypal
retinoid-inducible gene Rarb2 is dependent on P-TEFb activity;
(iii) RAR, but not RXR, associates to transcribed regions of the
Rarb2 locus in a cdk9-dependent manner and colocalizes with
elongating RNApol II; (iv) BRD4 and AF9 facilitate retinoid-
induced transcription and exert distinct biological functions in
retinoid-mediated neuronal differentiation. Thus monomeric
RAR may be involved in promoter-pausing release and possibly
transcriptional elongation as shown by our data. Such a dual
function has been suggested recently for the transcription factor c-
Myc [53]. Whether the RAR/elongation complex serves structural
and/or functional functions call for further investigations, which
will require to take into account the multiple functions of
components of this multimeric complex and the use of simplified
transcription systems.
Supporting Information
Figure S1 RAR interaction with isolated RAR domains and
functional interference with NAP1L2. (A) Various domains of
RARa were expressed as fusion proteins to GST (left panel) and
used as baits for 35S-labeled RARa AF-1. Protein bound on beads
are visualized by autoradiography, in comparison to 10% input
(Input). CB: Coomassie Blue staining of RAR derivatives adsorbed
on glutathione-sepharose beads. (B) Coimmunoprecipitation of
AF9 and RARa in HeLa cells. HeLa cells were cotransfected with
expression vectors coding for either wtRARa (wt) or N-terminally
truncated RAR (DAF-1) together with an empty pCMV-36FLAG
plasmid (Mock), or pCMV-36FLAG containing a AF9 cDNA
insert. Cell lysates were immunoprecipitated (IP) with an anti-
FLAG M2 affinity resin, and immunoprecipitates, as well as cell
lysates (Input), were analyzed by western blotting with an anti-
RAR antibody. The numbers (ratio) are the ratio of RAR to AF9
detected by western blotting and quantified by densitometric
analysis. (C) P19 cells were transfected with the indicated amounts
of a NAP1L2 expression vector for 24 hours and Rarb2 gene
expression level was assayed after a 4-hour treatment with 1 mM
atRA, using a Taqman-based RT-QPCR assay. The basal
expression level in untreated cells was arbitrarily set to 1 and
data are expressed as the mean6SEM (n= 3). *, p,0.05; **,
p,0.01; ***, p,0.005.
(TIFF)
Figure S2 Retinoic acid induces a neuronal differentiation
program in EC P19 cells. (A) Microarray gene expression analysis
of RA-stimulated P19 cells. A mRNA expression scatter plot was
obtained from gene-level interpretation of microarray data (left
panel), out of which the 10 most up- or down-regulated genes were
identified (right panel). The two thick green lines in the scatter plot
indicate a fold change greater than 2. (B) Genes whose expression
was modulated more that 2-fold were clustered using the Gene
Ontology functional annotation table [1].
(TIFF)
Figure S3 Basal gene expression in Af9- or Brd4-depleted P19
cells. P19wt, P19Brd4(2) or P19Af9(2) cells were treated for 4 hours
with 100 nM TTNPB, and mRNAs were extracted and analyzed
on Agilent microarrays. Basal expression level was set to 1 in the
P19wt background, and genes deregulated by more than 2-fold in
both P19Brd4(2) or P19Af9(2) backgrounds were identified using the
Genespring software. An entity list consisting of all genes
displaying an altered expression in either P19Brd4(2) or P19Af9(2)
cells was generated, and their expression level in each background
was extracted from microarray data. These expression values,
expressed as fold-change over basal in P19wt cells, were processed
and used to generate heatmaps with MeV [2]. Genes displaying a
FC.5 in the P19Brd4(2) background (top) or in the P19Af9(2)
background (bottom) were analyzed using Gene Ontology
Functional Annotation Tables and the KEGG database [1]. The
most significant terms are indicated. Finally, genes displaying a
FC.5 in the P19Brd4(2) background or in the P19Af9(2)
background were compared and genes similarly affected by both
knockdowns were identified, and subjected to GO FAT and
KEGG annotations. These analyses appear in the middle of the
figure. Green: down-regulated; red: up-regulated. Raw data are
available in Table S3.
(TIFF)
Figure S4 atRA and TTNBP elicits a similar transcriptional
program in EC P19 cells. Genes that were modulated with a
FC.1.5 at least in one condition (1 mM atRA or 1 mM TTNPB)
were identified by data analysis in Genespring v12.0 and the gene
list was exported as a text file from this software (available in Table
S2). A partial heat map corresponding to upregulated genes
(FC.2 in atRA-treated P19) classified by order of induction was
generated from this worksheet using MeV and is shown
fragmented for visualization purposes from left to right. Up- or
RAR and the Elongation Complex
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downregulated genes (FC.2) are indicated in red or green
respectively.
(TIFF)
Figure S5 Gene expression induction in an Af9- or Brd4-
deficient cellular background. (A) Scatter plot representation of the
gene expression pattern in wild type P19 (P19 wt), AF9-depleted
P19 or BRD4-depleted P19 (P19Af9(2) or P19Brd4(2) respectively).
The two thick green lines in scatter plots indicate a fold change
greater than 2. (B) The expression of the neuronal differentiation
marker NF160 was assessed by western blot analysis 96 hours after
the initiation of neuronal differentiation as previously described
[3].
(TIFF)
Figure S6 BRD4 and AF9 binds to RAR as distinct complexes.
(A) Western blot of P19 whole cell extracts (100 mg proteins). P19
cells were grown under standard conditions and whole cell extracts
were prepared as described in the Materials & Methods section.
Proteins were resolved on 4–15% polyacrylamide gels and
analyzed by western blotting using an anti-RAR (Santa Cruz,
sc551), an anti-Brd4 (Active Motif) or an anti-AF9 (Bethyl A300-
595A) antibody. (B) Coimmunoprecipitations assays. RAR was
immunoprecipitated with an anti-RAR antibody (Santa-Cruz,
sc551). Isolated complexes were resolved by 8% SDS-PAGE and
analyzed by western-blotting using an anti-Brd4 (Active Motif) or
an anti-AF9 antibody (Bethyl A300-595A). Reciprocal immuno-
precipitations were carried out using an anti-Brd4 antibody (Santa
Cruz H250) or a mix of anti-AF9 antibodies (Bethyl Labs). Input:
10% of total material (500 mg proteins); IgG: non-immune sera
(rabbit); IP: immunoprecipitation with the indicated antibody.
(TIFF)
Table S1 Gene chromosomal coordinates and associated regions
amplified by PCR in ChIP experiments. * Taken from [4]. **TSR
coordinates are extracted from databases using Genomatix
Eldorado. TSR amplicons were defined by extending the
identified TSR with +/250 bp. RARE motif search were carried
out using this extended sequence and PCR primers were designed
to optimally amplify this sequence using Primer3plus. When
multiple potential RARE were detected, primers were designed to
encompass all RAREs whenever possible. *** as defined by
MathInspector scanning of the sequence using the V$RXRF
matrix.
(XLSX)
Table S2 Gene basal expression in the P19wt, P19Brd4(2) or
P19Af9(2) background. Genes that were modulated with FC.2 at
least in one condition (shAF9 or shBrd4 vs wtP19) were identified
by data analysis at the gene level in Genespring v12.0. The gene
list was exported as a text file from this software. Gene expression
levels in wtP19 were set to arbitrarily set to 1 and gene expression
levels observed in either the AF9- or the BRD4-depleted
background were expressed relative to this control. A heatmap
corresponding to up- or down-regulated genes were generated
from this worksheet using MeV and appears in the Supporting
information files (Fig. S3).
(XLSX)
Table S3 atRA and TTNPB elicit a similar transcriptional
response in P19 EC cells. Genes that were modulated with
FC.1.5 at least in one condition (1 mM atRA or 1 mM TTNPB)
were identified by data analysis in Genespring v12.0 and the gene
list was exported as a text file from this software. Up- or
downregulated genes (FC.2) are indicated in red or green
respectively. A partial heat map corresponding to upregulated
genes was generated from this worksheet using MeV and appears
in Figure S3.
(XLSX)
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